Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 15;13(2):483.
doi: 10.3390/biomedicines13020483.

Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in 2018-2023 and the Impact of Molecular Diagnostics on Chemotherapy in Clinical Practice

Sonja Millert-Kalińska  1   2 , Małgorzata Stawicka-Niełacna  3   4 , Lidia Tomczak  2 , Dominik Pruski  2 , Marcin Przybylski  2 , Karolina Jaszczyńska-Nowinka  3 , Grzegorz Poprawski  3 , Radosław Mądry  3
Affiliations

Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in 2018-2023 and the Impact of Molecular Diagnostics on Chemotherapy in Clinical Practice

Sonja Millert-Kalińska et al. Biomedicines. .

Abstract

Background: High-grade advanced ovarian, fallopian tube, and primary peritoneal (HGAOC) cancers require both surgical and systemic treatment. The introduction of polyADP-ribose polymerase inhibitors (PARPis) has significantly improved outcomes. This study presents an analysis of HGAOC patients treated at a single center, following updated guidelines. Methods: We observed 437 women newly diagnosed with HGAOC at the Department of Gynecological Oncology between January 2018 and December 2023. Results: Since November 2022, first-line treatment has included bevacizumab and PARPi, regardless of residual disease post-cytoreductive surgery. In both BRCA1/2-mutated and non-mutated groups, PARPi-based regimens increased significantly after May 2021 (p < 0.01). Recurrence number emerged as a strong prognostic factor for survival (p < 0.001), with each recurrence raising mortality risk by 80%. Median survival was 21 months for paclitaxel + platinum derivatives (PC), 27 months for PC + bevacizumab (BEV), and 30 months for PC + BEV + PARPi. Conclusions: The rapid adoption of modern therapies at our center has aligned treatment strategies with HRD status and global standards. However, variations in financial regulations and drug accessibility persist across countries. Despite these challenges, physicians should prioritize the most effective therapies available.

Keywords: HGAOC; OC; high-grade advanced ovarian cancer; molecular diagnostics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Analyzed periods in correlation with changes in the therapeutic program in Poland. OLA—olaparib; BEV—bevacizumab; NIRA—niraparib.
Scheme 1
Scheme 1
Study design considering inclusion and exclusion criteria. OC—ovarian cancer, primary peritoneal and fallopian tube cancer; n—number.
Figure 2
Figure 2
Survival probability of patients treated with PARPi depends on the number of recurrences.
Figure 3
Figure 3
Survival times of patients treated with different chemotherapy regimens.
See this image and copyright information in PMC

References

    1. The Global Cancer Observatory GLOBOCAN 2020: International Agency Research on Cancer. Int. Agency Res. Cancer. 2020;509:336–343.
    1. Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 2019;144:1941–1953. doi: 10.1002/ijc.31937. - DOI - PubMed
    1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer. N. Engl. J. Med. 1996;334:1–6. doi: 10.1056/NEJM199601043340101. - DOI - PubMed
    1. du Bois A., Lück H.J., Meier W., Adams H.P., Mobus V., Costa S., Bauknecht T., Richter B., Warm M., Schroder W., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 2003;95:1320–1329. doi: 10.1093/jnci/djg036. - DOI - PubMed
    1. Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., Mannel R.S., Homesley H.D., Fowler J., Greer B.E., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011;365:2473–2483. doi: 10.1056/NEJMoa1104390. - DOI - PubMed

LinkOut - more resources